Sangart, a privately held biopharmaceutical company focused on oxygen-therapeutic agents, has appointed three new members to its executive team.
Frank Booth, MA, MSc, BM, BCh, FACS, was appointed to chief medical officer. Booth has more than 20 years of experience as a trauma and critical care surgeon and as a clinical investigator. Previously he worked in clinical development roles at Novo Nordisk and Eli Lilly.
Mary Rose Keller was appointed vice president of clinical operations, responsible for the execution of all clinical programs, including sickle cell, trauma and future treatments at Sangart. She has more than 25 years of experience in clinical research and trial execution and has been involved with numerous, successful regulatory submissions for companies such as Agouron, Pfizer and Shire Pharmaceuticals.
Carmen Betancourt-Riche, MBA, was appointed vice president of regulatory affairs and quality assurance, overseeing the design and execution of Sangart's global regulatory and quality assurance strategy. She more than 34 years of drug development experience in the pharmaceutical industry and has held senior regulatory roles at BioMarin Pharmaceutical, Cerexa, Coulter Pharmaceuticals, Genentech, KaloBios Pharmaceuticals and VaxGen.